4-甲氧基-(+)-3-甲基哌啶 | 373604-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-甲氧基-(+)-3-甲基哌啶
• 英文名称: 4-Methoxy-3-methylpiperidine
• CAS: 373604-48-9
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: IANZRNIJJWLDGA-UHFFFAOYSA-N

物化性质

• 沸点：
  164.4±33.0 °C(Predicted)
• 密度：
  0.91±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为产物：
  描述：

  N-Boc-3-甲基-4-羟基哌啶 在 盐酸 、 sodium hydride 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 4-甲氧基-(+)-3-甲基哌啶
  参考文献：
  名称：

  [EN] HEPATITIS B ANTIVIRAL AGENTS
  [FR] AGENTS ANTIVIRAUX DE L'HÉPATITE B

  摘要：

  本发明包括一种抑制、压制或预防需要的人体内HBV感染的方法，包括向个体投给治疗有效量的至少一种本发明的化合物。

  公开号：

  WO2013096744A1

文献信息

• 8-Substituted isoquinoline derivative and the use thereof
  申请人：Kaneko Shunsuke

  公开号：US20100261701A1

  公开（公告）日：2010-10-14

  The present invention relates to a compound represented by the following formula (1): wherein D 1 , A 1 , D 2 , R 1 , D 3 , and R 2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.

  本发明涉及一种由以下式（1）表示的化合物： 其中D1，A1，D2，R1，D3和R2分别具有与本说明书中定义的相同含义或其盐。由式（1）表示的化合物或其盐具有IKKβ抑制活性等，对于预防和/或治疗IKKβ相关疾病或症状等方面是有用的。
• [EN] 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL] ET COMPOSÉS ASSOCIÉS UTILISÉS COMME MODULATEURS POUR L'ÉPISSAGE DES ACIDES NUCÉIQUES ET POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：REMIX THERAPEUTICS INC

  公开号：WO2022006543A1

  公开（公告）日：2022-01-06

  The present disclosure features compounds e.g. of formula (I-a) and similar compounds e.g. of formulae (l-g), (l-i), (l-j), (III), (lll-a), (III- b) and (IV) disclosed herein and other related compounds, and pharmaceutical compositions thereof. The present disclosure further discloses said compounds and their compositions for use in methods of modulating nucleic acid splicing, as well as said compounds for use in methods of treating e.g.: • proliferative diseases, such as e.g. cancer, benign neoplasms or angiogenesis, • neurological diseases or disorders, such as e.g. Huntington's disease, • autoimmune diseases or disorders, immunodeficiency diseases or disorders, lysosomal storage disease or disorder, cardiovascular diseases or disorders, metabolic diseases or disorders, respiratory diseases or disorders, renal diseases or disorders, or infectious diseases. Exemplary compounds are e.g. 5-[5-(piperidin-4-y l)thieno[3,2- c]pyrazol-2-yl]indazole and 5-[2-(piperidin-4-yl)-[1,2,4]triazolo[3,2-b] [1,3]thiazol-5-yl]indazole derivatives and related compounds.

  本公开涉及化合物，例如式(I-a)的化合物以及类似的化合物，例如式(l-g)，(l-i)，(l-j)，(III)，(lll-a)，(III-b)和(IV)以及其他相关化合物及其药物组合物。本公开进一步揭示了所述化合物及其组合物用于调节核酸剪接的方法，以及所述化合物用于治疗的方法，例如： •增殖性疾病，例如癌症、良性肿瘤或血管生成， •神经疾病或障碍，例如亨廷顿病， •自身免疫疾病或障碍，免疫缺陷疾病或障碍，溶酶体贮积病或障碍，心血管疾病或障碍，代谢性疾病或障碍，呼吸系统疾病或障碍，肾脏疾病或障碍，或传染病。示例化合物包括例如5-[5-(哌啶-4-基)噻吩[3,2-c]吡唑-2-基]吲唑和5-[2-(哌啶-4-基)-[1,2,4]三唑噻吩[3,2-b][1,3]噻唑-5-基]吲唑衍生物及相关化合物。
• Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
  申请人：WOCKHARDT RESEARCH CENTER

  公开号：US20020165227A1

  公开（公告）日：2002-11-07

  The present invention relates to optically pure 8-(substituted piperidino)-benzo[i,j]quinolizines, their isomers, derivatives, salts, pseudopolymorphs, polymorphs prodrugs and hydrates thereof, to processes for their preparation, and to pharmaceutical compositions comprising 8-(substituted piperidino)-benzo[i,j]quinolizines their isomers, derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof. These compounds and compositions possess potent activity in treating local and systemic infections, particularly infections caused by sensitive and resistant Gram-positive organism infections, Gram-negative organism infections, mycobacterial infections and nosocomial pathogens, and particularly those belonging to the staphylococcus, streptococcus and enterococcus groups. Methods for treating the diseases and disorders arising from the foregoing infections in humans and animals are described by administering the compounds of the invention to said humans and animals.

  本发明涉及光学纯的8-(取代哌啶基)-苯[i,j]喹啉，它们的异构体、衍生物、盐、伪多晶体、多晶体、前药和水合物，以及它们的制备方法和包含8-(取代哌啶基)-苯[i,j]喹啉、它们的异构体、衍生物、盐、伪多晶体、多晶体和水合物的药物组合物。这些化合物和组合物在治疗局部和全身感染方面具有强效活性，特别是对敏感和耐药革兰氏阳性菌感染、革兰氏阴性菌感染、分枝杆菌感染和医院感染病原体，特别是属于葡萄球菌、链球菌和肠球菌群的感染具有活性。通过将本发明的化合物用于人类和动物治疗上述感染引起的疾病和疾病的方法也被描述。
• AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS
  申请人：Bryan Marian C.

  公开号：US20160016948A1

  公开（公告）日：2016-01-21

  This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.

  本发明涉及一种新型化合物，它们是T790M含有EGFR突变体的抑制剂，包括含有它们的制药组合物、它们的制备过程以及它们在预防或治疗癌症的治疗中的使用。
• 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP2366699A1

  公开（公告）日：2011-09-21

  The present invention relates to a compound represented by the following formula (1): wherein D1, A1, D2, R1, D3, and R2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.

  本发明涉及下式（1）所代表的化合物： 其中 D1、A1、D2、R1、D3 和 R2 各具有与本说明书中定义相同的含义或其盐。式（1）代表的化合物或其盐具有 IKKβ 抑制活性等，可用于预防和/或治疗 IKKβ 相关疾病或症状等。